Bottom of the range looks a good place to buy GSK. Underperforming though and needs some impetus for share price growth.
CMP-883 BUY ON EVERY DIP STOP LOSS-575 TARGET-1100/1200/1400.
CMP-2548 STOP LOSS-2255 TARGET-3048/3400/4300.
Next time when you see those upside spikes is a chart, that is and extremely bullish sign. Maybe some insider buys! Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology that enables the functional selection of stem cells, and Quoin Pharmaceuticals Inc. (“Quoin”), a privately held specialty pharmaceutical company, today announced that...
Catalyst Seneca Biopharma, Inc. (Nasdaq: SNCA) entered into a agreement with a privately held company Leading BioSciences, Inc. (“LBS” for a merger with to form Palisade Bio, Inc. SNCA has broken out of a descending channel and retested the upper trend line. The idea is self explanatory targets and stop loss is marked on the chart. A good risk management is...
Catalyst Pharmaceuticals is a biopharmaceutical company that specializes in therapies for rare neurological and neuromuscular diseases. It announced its fourth-quarter and 2020 financial results on March 15, 2021, reporting a 16% increase in revenue for fiscal 2020 and a 30% increase in operating income. (investopedia.com) The company posted adjusted earnings of...
AstraZeneca (AZN), W1: Support line + Bollinger bands + Hammer + Sell off
ACAD LONG SET UP, ACAD Gapped down over 25% to a New 52 week low. Price should bounce and fill in the Gap in the market ACAD also filled its previous Buy gap from Sep 4th 2019 Title: Buy ACAD (ACADIA Pharmaceuticals) Asset: Stock Platform: Robinhood/WeBull/Etrade/ 401k account Symbol: ACAD Type: Buy Market Execution / Buy Limit Time Frame: 1D Entry Price...
The stock is weak and more so it has been exposed to the shock of heavy volume price level and now facing rejection at higher level. Let it cross 604.20 level then we can take the trade to ride the profit.
$KMPH has very weak support and could retrace much lower regions in near completion of a head and shoulders formation. All signs are grossly bearish, including many large-scale sell orders having been placed in the last five days. The bigger investors have pulled the rug-- Target new entries much lower on this position if possible. Best, BDR
Merck is one of my favorite pharmaceutical companies. As far as I can tell, it a genuinely ethical and well-managed company with an above-average ESG rating. Merck has executed pretty consistently, with an average of 2% annual sales growth, 2.5% annual dividend growth, 3% annual earnings growth, and 4% annual free cash flow growth over the past several...
***Do your own research, this is just for educational purpose. Not an investment advice.
ZYNERBA PHARMACEUTICALS INC NEXT MOVE
Don't sleep on this one! **Not financial advice, do your own research!**
I Hate Trading Pharma But... MRK BUYZONE = 74 - 76 Cost Avg Down (CAD) = 72 - 70 1st Target = 79 2nd Target = 82 3rd Target = 86 HODL Target = ATH ______________________________________________________________________________________________________________________ This content is for informational, educational and entertainment purposes only. This is not in...
S/R flip seems really probable here I went long looking for at least $2.30
NASDAQ:VTGN This isn't financial advice (hell no). I like this stock. The company has potential. This is a nice buying opportunity in non-expert opinion. So, I'm scooping up before their phase 3 trials.